These patents are the foundation for our Univercyte™ technology platform. & However, each alternative has potential disadvantages as well. Therefore, it is possible to generate clonal lineages of these cells in vitro. Flow cytometry shows purity indistinguishable from 100%. & Our inventions relating to iTR biologics disclose both DNA and RNA-based strategies. As a result, we have not yet assembled an infrastructure for sales and marketing. The expiration dates of the HyStem® patents range from 2023 to 2027. & The requirements governing drug pricing vary widely from country to country. Two full-time and one part-time employees hold Ph. 9679;Third-party manufacturers could breach or terminate their agreements with us. & 9679;We will face similar regulatory issues in foreign countries. & The use of hES cells may give rise to religious, moral, and ethical issues. In addition, there is a natural transition period when a new third party commences work. We do not have current plans to pay any cash dividends on our common stock. There is no guarantee that securities analysts will cover our common stock. See Note 4 to our consolidated financial statements included elsewhere in this Report. &